All Stories

  1. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Sara Elena Rebuzzi, Melissa Bersanelli, Dr Sebastiano Buti

  2. Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

    Article • Case Reports in Oncological Medicine, February 2019, Hindawi Publishing Corporation

    Corrado Ficorella, Melissa Bersanelli, Alessio Cortellini

  3. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

    Article • Immunotherapy, October 2018, Future Medicine

    Melissa Bersanelli, GAETANO FACCHINI, Dr Sebastiano Buti

  4. Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

    Article • Cancer Management and Research, September 2018, Dove Medical Press

    Melissa Bersanelli, Dr Sebastiano Buti

  5. Patient performance status and cancer immunotherapy efficacy: a meta-analysis

    Article • Cancer Immunology Immunotherapy, August 2018, Springer Science + Business Media

    Melissa Bersanelli, Dr Sebastiano Buti

  6. Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

    Article • Immunotherapy, July 2018, Future Medicine

    Melissa Bersanelli, MD Letizia Gnetti, Dr Sebastiano Buti

  7. The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade

    Article • Immunotherapy, November 2017, Future Medicine

    Melissa Bersanelli, Dr Sebastiano Buti

  8. Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

    Article • Therapeutic Advances in Medical Oncology, August 2017, SAGE Publications

    Melissa Bersanelli, Dr Sebastiano Buti

  9. First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

    Article • Clinical Genitourinary Cancer, August 2017, Elsevier

    GAETANO FACCHINI, Melissa Bersanelli, Dr Sebastiano Buti

  10. Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

    Article • Therapeutics and Clinical Risk Management, June 2017, Dove Medical Press

    Melissa Bersanelli, Dr Sebastiano Buti

  11. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

    Article • Core Evidence, September 2016, Dove Medical Press

    Melissa Bersanelli, Dr Sebastiano Buti